Melanoma Matters28 Des 2025

Ep 75: Immune-mediated Myocarditis

Summary

In this (longest to-date) episode, James and Sapna delve into the not-so-rare occurence of immune-mediated myocarditis, particularly in the context of immune checkpoint inhibitors. The hosts discuss grading systems, management strategies, and the challenges of diagnosing and treating myocarditis. They emphasize the importance of close follow-up and the need for collaboration with cardiologists.

Keywords

myocarditis, immune checkpoint inhibitors, cardiology, personalized treatment, grading systems

Takeaways

Grading systems for myocarditis are essential but can be blunt tools.
Personalized treatment approaches are crucial for managing myocarditis.
Collaboration with cardiologists is vital for effective management.
High-dose steroids are often the first line of treatment for myocarditis.
There is a need for more prospective data on myocarditis management.
Ruxolitinib and abatacept are potential second-line treatments.
Monitoring troponin levels can help assess treatment effectiveness.
The role of immunosuppressive drugs in myocarditis is still being studied.
Early involvement of cardiologists can improve patient outcomes.
Understanding the biology of myocarditis can lead to better treatment strategies.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Sep 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Aug 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Aug 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Aug 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Jul 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Jul 35min

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Jun 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Jun 1h 4min